XPhyto to Present at Virtual Life Sciences Forum on September 17

Rhea-AI Summary

XPhyto Therapeutics Corp. (CSE:XPHY) (OTCQB:XPHYF) will present at the Virtual Life Sciences Forum on September 17, 2020, at 1:00 PM Eastern Time. CEO Hugh Rogers will discuss developments in Germany regarding a rapid COVID-19 screening test and innovative drug delivery methods. The company collaborates with 3a-Diagnostics GmbH on a point-of-care test for COVID-19 viral RNA detection. Additionally, XPhyto is advancing dosage forms for conventional and cannabis-based narcotics. The event is open to investors, with registration available online.

VANCOUVER, BC / ACCESSWIRE / September 14, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY) (FSE:4XT) (OTCQB:XPHYF) ("XPhyto" or the "Company") is pleased to announce the company will be presenting at the Virtual Life Sciences Forum, hosted by the OTC Markets Group, on September 17 at 1:00 pm Eastern Time.

Recently listed on the OTCQB, XPhyto trades under the symbol "XPHYF". XPhyto's CEO, Hugh Rogers, will discuss the company's developments in Germany on its rapid COVID-19 (SARS-CoV-2) screening test and next generation drug delivery programs. XPhyto and its exclusive diagnostic partner, 3a-Diagnostics GmbH ("3a"), are developing a rapid, disposable, point-of-care lateral flow screening test to detect COVID-19 viral RNA from patient saliva samples. XPhyto and its wholly owned German subsidiary, Vektor Pharma TF GmbH, are developing transdermal and oral dissolvable dosage forms for the delivery of conventional and cannabis-based narcotics for neurological applications.

The event is open to all. Investors can register and participate via the following link: https://lifesciencesinvestorforum.gcs-web.com/events/event-details/agenda.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

About XPhyto Therapeutics Corp.

XPhyto is a diversified bioscience company with strategic assets and investments in the field of next generation drug delivery and rapid pathogen screening systems, as well as medical cannabis opportunities focused on European markets. Through its 100% owned subsidiaries and exclusive collaboration agreements, XPhyto is pursuing clinical programs for the transdermal and dissolvable oral delivery of conventional and cannabis based narcotics for neurological applications, as well as rapid dissolvable oral biosensor and lateral flow assay-based screening tests for dental health applications and high-risk pandemic threats such as SARS-COV-2 (COVID19), H1N1 (swine flu) and H5N1 (avian flu). XPhyto has two exclusive cannabis collaborations with the Technical University of Munich, and two exclusive 5-year engagements with the University of Alberta, Faculty of Pharmacy and Pharmaceutical Sciences for cannabis extraction, isolation, formulation, and analytical testing.

ON BEHALF OF THE BOARD

"Hugh Rogers" Hugh Rogers, CEO and Director

Investor Inquiries:

Mr. Knox Henderson
Tel: 604-551-2360
info@xphyto.com
www.xphyto.com

Forward looking statements

This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "develop", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company's goal of building a successful diagnostic, drug delivery, and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not succeed in developing a commercial product; that the sale of products may not be a viable business; that the Company may be unable to scale its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; currency risks; competition; international risks; and other risks beyond the Company's control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: XPhyto Therapeutics Corp.

View source version on accesswire.com:
https://www.accesswire.com/605987/XPhyto-to-Present-at-Virtual-Life-Sciences-Forum-on-September-17

FAQ

When is XPhyto presenting at the Virtual Life Sciences Forum?

XPhyto Therapeutics Corp. will present on September 17, 2020, at 1:00 PM Eastern Time.

What will XPhyto discuss at the Virtual Life Sciences Forum?

XPhyto will discuss developments related to a rapid COVID-19 screening test and next-generation drug delivery programs.

What is the ticker symbol for XPhyto Therapeutics?

XPhyto trades under the ticker symbol 'XPHYF' on the OTCQB.

Who is collaborating with XPhyto on the COVID-19 screening test?

XPhyto is collaborating with 3a-Diagnostics GmbH on a rapid, point-of-care COVID-19 screening test.

What types of drug delivery systems is XPhyto developing?

XPhyto is developing transdermal and oral dissolvable dosage forms for conventional and cannabis-based narcotics.